Barbital

Barbital

Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a682221
Routes of administration	Oral
ATC code	N05CA04 (WHO)
Legal status
Legal status	CA: Schedule IV DE: Anlage III (Prescription only) US: Schedule IV
Pharmacokinetic data
Biological half-life	30.3 (± 3.2) hours
Identifiers
IUPAC name 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number	57-44-3 Y
PubChem (CID)	2294
DrugBank	DB01483 Y
ChemSpider	2206 Y
UNII	5WZ53ENE2P Y
KEGG	D01740 Y
ChEBI	CHEBI:31252 Y
ChEMBL	CHEMBL444 Y
ECHA InfoCard	100.000.301
Chemical and physical data
Formula	C8H12N2O3
Molar mass	184.193 g/mol
3D model (Jmol)	Interactive image
SMILES O=C1NC(=O)NC(=O)C1(CC)CC
InChI InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13) Y Key:FTOAOBMCPZCFFF-UHFFFAOYSA-N Y
(verify)

Barbital (as known in the United States) or barbitone (as known elsewhere), marketed under the brand names Veronal for the pure acid and Medinal for the sodium salt, was the first commercially available barbiturate. It was used as a sleeping aid (hypnotic) from 1903 until the mid-1950s. The chemical names for barbitone are diethylmalonyl urea or diethylbarbituric acid; hence, the sodium salt (known as medinal, a genericised trademark in the United Kingdom) is known also as sodium diethylbarbiturate.

Synthesis

Barbitone was first synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering, who published their discovery in 1903. Barbitone was prepared by condensing diethylmalonic ester with urea in the presence of sodium ethoxide, and then by adding at least two molar equivalents of ethyl iodide to the silver salt of malonylurea or possibly to a basic solution of the acid. The result was an odorless, slightly bitter, white crystalline powder.

Barbitone can also be synthesized in a condensation reaction from urea and diethyl-2,2-diethylmalonate, a diethyl malonate derivative:

Marketing

Bottle for 'Veronal' crystals, named after the Italian city of Verona, was the first commercially available barbiturate, manufactured by Bayer.

Barbitone was marketed in 1904 by the Bayer company as “Veronal”. A soluble salt of barbitone was marketed by the Schering company as “Medinal.” It was dispensed for “insomnia induced by nervous excitability”. It was provided in either capsules or cachets. The therapeutic dose was ten to fifteen grains (0.65-0.97 grams). 3.5 to 4.4 grams is the deadly dose but sleep has also been prolonged up to ten days with recovery.

Pharmacology

Barbitone was considered to be a great improvement over the existing hypnotics. Its taste was slightly bitter, but better than the strong, unpleasant taste of the commonly used bromides. It had few side effects, and its therapeutic dose was far below the toxic dose. However, prolonged usage resulted in tolerance to the drug, requiring higher doses to reach the desired effect. "I'm literally saturated with it," the Russian tsarina Alexandra Feodeorovna confessed to a friend. Fatal overdoses of this slow-acting hypnotic were not uncommon. Pioneering aviator Arthur Whitten Brown (of "Alcock and Brown" fame) died of an accidental overdose.

pH Buffer

Solutions of sodium barbital have also been used as pH buffers for biological research, e.g., in immunoelectrophoresis or in fixative solutions. As barbital is a controlled substance, barbital-based buffers have largely been replaced by other substances.

Further reading

• (English) Dombrowski SM, Krishnan R, Witte M,Maitra S, Diesing C, et al. 1998. Constitutive and barbital-induced expression of the CYP6A2 allele of a high producerstrain of CYP6A2 in the genetic backgroundof a low producer strain. Gene221:69–77.